Rozendaal, Thierry P. P. van den Bosch, Xinguo Jiang, Kathryn Logronio, Angela Z. Liu, Yun - Ru Liu, Yuki Nagasaki, Makoto Murakami, Anne Onrust - Van Schoonhoven, Asabi Leliveld, Disha Vadgama, Hedwig Langeveld, Rogier van Wijck, Eric Bindels, Jan von der Thüsen , Antien Mooyaart , Febe van Maldegem, Claudia M. Brenis, Stijn Verwaerde, Rudi W. Hendriks, Bart N. Lambrecht, Dirk J. Grünhagen, Cornelis Verhoef, Joachim G. J. V. Aerts, Li - Fen Lee, Kan V. Lu, Ralph Stadhouders, Floris Dammeijer. Forward - Looking Statements: This press release contains forward - looking statements, including statements regarding the development of AI - 306, anticipated regulatory milestones including the timing of the IND filing, and the potential clinical and commercial opportunity for PLA2G2D - d irected therapy. Actual results may differ materially from those expressed or implied by these statements as a result of various factors, including the risks inherent in preclinical and clinical drug development. Apeximmune undertakes no obligation to update these statements. Media Contact: Liz Wilkins, Capwell Communications , + 1 5 62 - 233 - 1263 , media@capwellcomm.com Company Contact: Li - Fen Lee, PhD, founder and CEO, Apeximmune Therapeutics, Inc. , llee@apeximmune.com Strategic Partnering Contact: Dan Ross, managing partner at BioPharma Capital , dan@biopharmacapital.com References 1. Haslam A, Olivier T, Prasad V. How many people in the US are eligible for and respond to checkpoint inhibitors: An empirical analysis. Int J Cancer . 2025; 156(12): 2352 - 2359. doi: 10.1002/ijc.35347 # # #